V
The FDA’s peptide circus is underway.
An advisory panel, stacked with RFK Jr.’s pro-peptide appointees, has voted to add BPC-157 and KPV to the bulk compounding list. This is despite FDA staff clinicians stating that there’s no convincing evidence. Central to the argument is whether allowing compounding will curtail the gray market or expose the public to unnecessary risk. Internally screaming.
Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.
Loading comments
Getting the conversation ready...
Most Popular
Most Popular
- Xbox’s former COO has ‘serious concerns’ about her abrupt departure
- One of Google’s Android partners turned 1.3 million set-top boxes into a botnet
- The 16GB Raspberry Pi 5 got another ‘unavoidable’ RAM price hike
- Squarespace is laying off 19 percent of employees
- The 2026 iPad Mini is a terrific tiny tablet — for a big price
